1,2,3,4-Tetrahydro-3-methyl-1 (isobutyl)-2,4-dioxo-6-(1h-pyrrolo[2,3,b]pyridin-3-ylmethyl)thieno[2,3,d]pyrimidine-5-carboxylic acid → 5-[[4-hydroxyisoxazolidin-2-yl]carbonyl]-3-methyl-1-(isobutyl)-6-[(1H-pyrrolo[2,3,b]pyridin-3-yl)methyl]thieno[2,3,d]pyrimidine-2,4(1H,3H)-dione

Participants

Reaction Steps

The title compound (55 mg) was prepared from the product of step b, (150 mg) by the method of example 1, step g), and (S)-4-hydroxyisoxazolidine, example 1 part b). MS (APCI) 484 [M+H]+. δ 1HDMSO 0.82-0.85 (6H,m), 2.03-2.13 (1H,m), 3.20-3.21 (3H,m), 3.53-3.68 (3H,m), 3.75-3.90 (2H,m), 4.00-4.18 (3H,m), 4.60-4.80 (1H,m), 5.50-5.55 (1H,m), 6.99-7.02 (1H,m), 7.41-7.44 (1H,m), 7.90-7.97 (1H,m), 8.18-8.20 (1H,m), 11.53 (1H,s,br)

Provenance & Evidence